BGBIO-Positive resultater i lungekreft presenteres torsdag 25/6

focuss

BGBIO 18.06.2020 kl 10:03 70386

Home / Media Centre / News
BERGENBIO TO PRESENT TOP LINE TRANSLATIONAL PHASE II DATA WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS AT NEXT GEN IMMUNO-ONCOLOGY CONGRESS
15.06.2020Share This Post
Bergen, Norway, 15 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that its abstract has been accepted for oral virtual presentation at the 3rd Annual Next Gen Immuno-Oncology Congress, which takes place from 25-26 June 2020.

The presentation to be given by Prof. Hani Gabra MD PhD, CMO BerGenBio, will provide an update of results from a phase II trial (BGBC008), evaluating bemcentinib in combination with MSD’s Keytruda® (pembrolizumab) in previously treated non-small cell lung cancer (NSCLC) patients with confirmed progression, including positive top line clinical and translational data from stage 1 of Cohort B in patients having failed prior immune checkpoint therapy.

The presentation will be available on the Company website in the Presentations section on 25 June: www.bergenbio.com/investors/presentations/

Title: Targeting AXL to leverage checkpoint immunotherapy: Updated results of the BGBC008 phase II study of bemcentinib and pembrolizumab in recurrent NSCLC

Date and time: 25 June 2020, 10am EST

Redigert 21.01.2021 kl 08:53 Du må logge inn for å svare

Dollargrisen

25.06.2020 kl 19:09 6650

Kom børsmelding nå:

https://newsweb.oslobors.no/message/508763

Redigert 21.01.2021 kl 08:42 Du må logge inn for å svare

risksøker

25.06.2020 kl 19:10 6614

Ærligtalt skrev Tja... Det er jo umulig å si- men spør du meg så bør store aktører innen Pharma og internasjonale in..

Jeg håper Godfrey kan gi en god og enkel forklaring om resultatet når han skal presentere for investorer nå kl 1900

Redigert 21.01.2021 kl 08:42 Du må logge inn for å svare

HP17

25.06.2020 kl 19:11 6607

Så utrolig nydelige ord. Dette smaker det suksess av

BERGENBIO ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCENTINIB IN COMBINATION WITH KEYTRUDA[®] IN checkpoint inhibitor refractory NSCLC PATIENTS

· 6 of 7 checkpoint inhibitor refractory cAXL-positive patients report clinical
benefit
· 12 evaluable patients for cAXL status, 7 of whom were cAXL-positive
· 2.5 fold improvement in mPFS in cAXL-positive patients
· Cohort A data-update mOS in cAXL-positive patients of 17.3 months.
· Data presented today at the virtual Next Gen Immuno-Oncology Congress

Redigert 21.01.2021 kl 08:42 Du må logge inn for å svare

Bulldog

25.06.2020 kl 19:13 6490

BERGENBIO : ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCENTINIB IN COMBINATION WITH KEYTRUDA IN checkpoint inhibitor refractory NSCLC PATIENTS
Richard Godfrey, Chief Executive Officer of BerGenBio, said: "This interim clinical and translational data adds further confidence to the potential patient benefit of selective AXL inhibition with bemcentinib, to reverse resistance to immune checkpoint inhibitors in selected cAXL-positive patients who have relapsed on immunotherapy. This would be a highly desirable alternative to the second-line chemotherapy standard-of-care. Top line data from expansion cohorts B2 and cohort C should be available towards the end of 2020."
https://www.marketscreener.com/BERGENBIO-ASA-34541487/news/BERGENBIO-ANNOUNCES-POSITIVE-interim-CLINICAL-AND-TRANSlaTIONAL-DATA-from-Phase-II-trial-of-BEMCEN-30825624/

Ble vist en dobbelposting ;)

Redigert 21.01.2021 kl 08:42 Du må logge inn for å svare

Ærligtalt

25.06.2020 kl 19:18 6368

Alle ser vel hvilken vei dette går nå ?

Partner, oppkjøp, u name it... Tvihold på aksjene!

Redigert 21.01.2021 kl 08:42 Du må logge inn for å svare

~~Slettet bruker~~

25.06.2020 kl 19:22 6307

Vurderer å kaste Mac´n ut av vinduet, for så å kjøpe ny tilgang til børskontoen i Mai 2021...Nå skal det sittes på hendene.

Covid 19 oppdatering senere i "sommer"

Redigert 21.01.2021 kl 08:42 Du må logge inn for å svare

Ærligtalt

25.06.2020 kl 19:24 6283

Mac?!?

- Trenger vel ikke et påskudd for å kaste den :)

Redigert 21.01.2021 kl 08:42 Du må logge inn for å svare

klaesp

25.06.2020 kl 19:31 6070

Bulldog skrev BERGENBIO : ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCEN..

Fantastisk, som jeg skrev tidligere i dag, denne dobles hvis positive resultater fra fase 2 studie. NÅ har vi fasiten, aksjen vil starte med en rolig dobling i første omgang.